About
Who We Are
Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of resistant and difficult to treat infections, as well as chronic and rare conditions that involve the over-expression of inflammation. Pravibismane, our first therapeutic candidate, has demonstrated broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs” identified by the US Centers for Disease Control and Prevention (CDC). This includes potent activity against carbapenem-resistant Enterobacteriaciae (CRE), ESKAPE pathogens, and antibiotic-resistant fungal pathogens. In addition, pravibismane has demonstrated a unique, broad spectrum ability to prevent and eradicate microbial biofilms. The dual action of antimicrobial / anti-biofilm activity has the potential to become a first-in-class, best-in-class clinical approach to treating serious and life-threatening infections. Importantly, the pathophysiology of many chronic conditions involves not only pathogenic microbes, but also chronic, dysfunctional inflammation. Pravibismane has a demonstrated anti-inflammatory immunomodulatory activity that helps to resolve the over-expression of inflammation.